Idioma:

Palliative radiotherapy for gross hematuria in patients with advanced cancer

Ogita, Mami ; Kawamori, Jiro ; Yamashita, Hideomi ; Nakagawa, Keiichi

Scientific reports, 2021-05, Vol.11 (1), p.9533-9533, Article 9533 [Periódico revisado por pares]

England: Nature Publishing Group

Texto completo disponível

Citações Citado por

Enviar para

Título:
Palliative radiotherapy for gross hematuria in patients with advanced cancer
Autor: Ogita, Mami ; Kawamori, Jiro ; Yamashita, Hideomi ; Nakagawa, Keiichi
Assuntos: Adult ; Aged ; Aged, 80 and over ; Blood Transfusion ; Blood transfusions ; Dose Fractionation, Radiation ; Female ; Fractionation ; Hematuria ; Hematuria - complications ; Hematuria - diagnosis ; Hematuria - radiotherapy ; Hematuria - therapy ; Humans ; Male ; Medical prognosis ; Middle Aged ; Multivariate analysis ; Neoplasms - complications ; Palliation ; Palliative Care ; Prognosis ; Radiation therapy ; Retrospective Studies ; Statistical analysis ; Transfusion ; Treatment Outcome
É parte de: Scientific reports, 2021-05, Vol.11 (1), p.9533-9533, Article 9533
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: This study assessed the efficacy of palliative radiotherapy for gross hematuria caused by advanced cancer. Patients who received palliative radiotherapy to control gross hematuria in two hospitals between October 2006 and May 2020 were retrospectively reviewed. We evaluated the gross hematuria response, gross hematuria control duration, blood transfusion rate, blood transfusion-free duration, and overall survival. Cox multivariate analysis was performed to examine factors associated with hematuria control duration. Fifty-three consecutive patients were included. The most frequently used dose fractionation regimen was 30 Gy in 10 fractions (BED = 39 Gy), followed by 20 Gy in 5 fractions (BED = 20 Gy). Forty patients (76%) became gross hematuria free. The median hematuria control duration was 4.3 months (95% confidence interval 1.9-6.6). Twenty-six patients received blood transfusion 3 months before radiotherapy; 17 of them (65%) were free from blood transfusion 1 month after radiotherapy. A high BED (≥ 36 Gy) was a statistically significant factor for hematuria control duration in the multivariate analysis (P = 0.02). Palliative radiotherapy can effectively relieve gross hematuria irrespective of the primary tumor site. A high BED may be recommended for a prolonged hematuria control duration if patients have a good prognosis.
Editor: England: Nature Publishing Group
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 6 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Palliative radiotherapy for gross hematuria in patients with advanced cancer

Ogita, Mami ; Kawamori, Jiro ; Yamashita, Hideomi ; Nakagawa, Keiichi

England: Nature Publishing Group

Buscando em bases de dados remotas. Favor aguardar.